Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Top Performing Drugs: Proceeding the Series
Top Performing Drugs: Proceeding the Series
Shots: Subsequent to our last year’s series titled “Top Performing Drugs of 2021”, PharmaShots presents a list of 12 high revenue-generating drugs With the ongoing pandemic playing an instrumental role in reshaping the life science industry now and then, it becomes increasingly onerous for the pharmaceutical industry to keep up with the growing global demands…
April 25, 2023
Insights+: The US FDA New Drug Approvals in March 2023
Insights+: The US FDA New Drug Approvals in March 2023
Shots: The US FDA approved 6 NDAs and 1 BLA in March 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 26 novel products in 2023 In March 2023, the major highlights drugs were, Tafinlar + Mekinist approval for BRAF V600E low-grade glioma, Zynyz for metastatic or…
April 19, 2023
Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)
Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)
Shots: With the indispensable transformations carried out over the years, the biopharma industry witnessed miraculous changes in operations, technology, and innovation. Such as inclination towards the Pharma 4.0 model, adoption of a multimodal building approach, and dependence on contract manufacturing While major companies like Johnson & Johnson, Roche, and Pfizer dominated the biopharma industry with…
April 13, 2023
Disease of the Month: Hemophilia
Disease of the Month: Hemophilia
Shots: To create a wholesome environment for the current and the future generation, it’s totally up to life science companies and decision-makers to embrace and integrate every prospect of the underlying disease conditions and address those issues to find cures To continue the series for disease of the month, PharmaShots brings this month a summary…
April 11, 2023
Insights+ Key Biosimilars Events of March 2023
Insights+ Key Biosimilars Events of March 2023
Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of March, Biogen launched Byooviz (biosimilar, ranibizumab) for…
April 5, 2023
PharmaShots' Key Highlights of First Quarter 2023
PharmaShots’ Key Highlights of First Quarter 2023
Shots: The first quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, Selecta and Sobi reported P-III trial (DISSOLVE I & II) results of SEL-212 for chronic refractory gout Starting with the latest acquisitions, Pfizer acquired Seagen for ~$43B. The first quarter of the year also showcases…
April 3, 2023
Insights+: EMA Marketing Authorization of New Drugs in February 2023
Insights+: EMA Marketing Authorization of New Drugs in February 2023
Shots: The EMA approved 7 New Chemical Entity (NCE) and 5 Biologic Drugs in February 2023, leading to treatments for patients and advances in the healthcare industry In February 2023, the major highlights drugs were Forxiga’s Approval for symptomatic chronic heart failure, Fintepla for adjunctive treatment of seizures associated with lennox-gastaut syndrome PharmaShots has compiled…
March 23, 2023
Top Performing Drug of 2021 - Darzalex (March Edition)
Top Performing Drug of 2021 – Darzalex (March Edition)
Shots: The ongoing series of the top-performing drugs of 2021 based on revenue is continued by Darzalex as the top-performing drug for March month Darzalex is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma in combination with different drugs The report summarizes the key features of Darzalex including revenue…
March 21, 2023
Insights+: The US FDA New Drug Approvals in February 2023
Insights+: The US FDA New Drug Approvals in February 2023
Shots: The US FDA approved 5 NDAs and 5 BLA in February 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 19 novel products in 2023 In February 2023, the major highlights drugs were, Tezspire (tezepelumab) approval for severe asthma, Altuviiio for hemophilia A PharmaShots has compiled…
March 15, 2023
Disease of the Month: IgA Nephropathy
Disease of the Month: IgA Nephropathy
Shots: To create a wholesome environment for the current and the future generation, it’s totally up to life science companies and decision-makers to embrace and integrate every prospect of the underlying disease conditions and address those issues to find cures PharmaShots brings this month an informative take on the disease IgA nephropathy Often known as…
March 13, 2023
Load more